Panelists discuss how the evolving treatment landscape for high-risk non–muscle-invasive bladder cancer (NMIBC) demands that urologists adapt to more complex delivery methods and integrate systemic therapies into care, emphasizing the need for patient education, new workflows, and multidisciplinary collaboration to ensure equitable access to emerging therapies across all practice settings.
Clean intermittent catheterization emerged as the second most commonly used bladder management method over time in both sexes.
In his latest YouTube masterclass, Dr. Ash Tewari shares his groundbreaking approach to nerve sparing prostate surgery, shedding light on the anatomy, surgical techniques, and innovations that make it possible.
The course addresses "unicorn cases" in the upper tract—unique and challenging situations lacking established guidelines or literature.
Data showed that African American men faced significant delays in treatment initiation.
Vikram M. Narayan, MD, discusses Emory's recent shift to Apple products, aimed at reducing physician burnout and improving patient interactions.
Justin Dubin, MD, discussed how patients' growing trust in digital tools could be leveraged to support lifestyle changes and improve health outcomes.
A panelist discusses how different abiraterone formulations require specific steroid combinations—prednisone with traditional abiraterone and prednisolone with microformulation—and the importance of following labeling recommendations.
A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.
Wang and Bukavina outline several cases of ctDNA's utility in the space.
Pezzella said she believes Neuspera offers a "smart, integrated, sophisticated alternative" for treating overactive bladder symptoms.
Panelists discuss the growing emphasis on combination therapies for high-risk non–muscle-invasive bladder cancer (NMIBC), highlighting their potential to overcome BCG resistance through synergistic mechanisms, while emphasizing the need for biomarker-driven personalization, careful management of adverse effects, and more robust data to guide optimal sequencing and patient selection.
Panelists discuss the complexities of treatment selection and sequencing in non–muscle-invasive bladder cancer (NMIBC) amid pending trial data, emphasizing the potential of emerging chemotherapy backbones, biomarker-driven personalization, and patient-centered decision-making to balance efficacy, quality of life, and evolving bladder-preserving options.
Mina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.
“With the right use, AI can and hopefully will play a massive role in patient education,” says Justin M. Dubin, MD.
Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.
According to Daniel D. Joyce, MD, MS, policy initiatives should focus on improving the value and efficiency of radiation.
Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.
A panelist discusses how patients having difficulty with traditional abiraterone fasting requirements can be switched to microsized abiraterone (taken with food) or off-label low-dose abiraterone with low-fat breakfast, though adherence to dietary restrictions remains challenging.
A panelist discusses how, for high-risk localized prostate cancer with questionable lymph node involvement, radiation therapy combined with systemic treatment may be preferable to radical prostatectomy due to the ability to treat a wider field of potential microscopic disease.
Justin M. Dubin, MD, outlines the current ways that artificial intelligence is being used in the male infertility space.
Bilal I. Chughtai, MD, walks through the design and potential implications of a pivotal trial of the Butterfly Prostatic Device.
Findings indicated that although trimodal therapy improved the quality of life for patients with muscle-invasive bladder cancer compared with cystectomy, its significantly higher cost made it not cost-effective.
Panelists discuss the evolving non–muscle-invasive bladder cancer (NMIBC) treatment landscape, emphasizing a shift away from BCG monotherapy for lower intermediate-risk patients toward combination and novel therapies for high-risk disease, while highlighting ongoing challenges related to toxicity, cost, BCG shortages, and the need for refined patient selection through biomarkers and precision medicine.
Panelists discuss novel intravesical drug delivery systems like TAR-200 and UGN-102 that enhance chemotherapy exposure and efficacy in non–muscle-invasive bladder cancer (NMIBC), while noting challenges in tolerability and administration, and highlighting their potential to improve patient outcomes and reduce invasive procedures.
A notable finding was that 35% of these NMIBC patients exhibited ctDNA positivity.
In this video, part 5 in a 5-part series, panelists examine the economic and logistical realities of bringing mitomycin for intravesical solution (Zusduri; formerly UGN-102) into private practice.
In this video, part 4 in a 5-part series, Nick Liu, MD, outlines key scenarios where surgical resection remains preferred for treating LG-IR-NMIBC.
In this video, part 3 in a 5-part series, panelists discuss the long-term clinical impact and health care system implications of mitomycin for intravesical solution (Zusduri; formerly UGN-102).
In this video, part 2 in a 5-part series, Nick Liu, MD, breaks down the formulation behind mitomycin for intravesical solution (Zusduri; formerly UGN-102).
